RET receptor tyrosine kinase gene mutations: Molecular biological, physiological and clinical aspects

European Journal of Clinical Investigation

Volumn 26, Issue 8, 1996, Pages 613-624

  Hoppener J W M ^a   Lips, C J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE;

GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; GENE STRUCTURE; HUMAN; MOLECULAR BIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTO ONCOGENE; REVIEW;

EID: 0029764522     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1996.tb02144.x     Document Type: Review

References (88)

1. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene RET by DNA rearrangement. Cell 1985;42:581-8.
2. Takahashi M, Cooper GM. RET transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987;7:1378-85.
3. Takahashi M, Inaguma Y, Hiai H, Hirose F. Developmentally regulated expression of a human 'finger'-containing gene encoded by the 5′ half of the ret transforming gene. Mol Cell Biol 1988;8:1853-6.
4. Takahashi M, Buma Y, Hiai H. Isolation of RET proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 1989;4:805-6.
5. Ishizaka Y, Itoh F, Tahira T et al. Human RET proto-oncogene mapped to chromosome 10q11.2. Oncogene 1989;4:1519-21.
6. Fusco A, Grieco M, Santoro M et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987;328:170-2.
7. Bongarzone I, Pierotti MA, Monzini N et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989;4:1457-62.
8. Grieco M, Santoro M, Berlingieri MT et al. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
9. Kwok JBJ, Gardner E, Warner JP, Ponder BAJ, Mulligan LM. Structural analysis of the human RET proto-oncogene using exon trapping. Oncogene 1993;8:2572-82.
10. Ceccherini I, Bocciardi R, Luo Y et al. Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochem Biophys Res Commun 1993;196:1288-95.
11. Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M. Characterization of RET proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 1990;5:97-102.
12. Tahira T, Ishizaka Y, Sugimura T, Nagao M. Expression of proto-RET mRNA in embryonic and adult rat tissues. Biochem Biophys Res Commun 1988;153:1290-5.
13. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993;119:1005-17.
14. Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J. Spatial and temporal expression of the RET proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 1995;10:191-8.
15. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
16. Schlessinger J, Ullrich A. Growth factor signalling by receptor tyrosine kinases. Neuron 1992;9:383-91.
17. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23.
18. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the RET proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-8.
19. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993;62:453-81.
20. Iwamoto T, Taniguchi M, Asai N, Ohkusu K, Nakashima I, Takahashi M. cDNA cloning of mouse RFT proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 1993;8:1087-91.
21. Kuma K, Iwabe N, Miyata T. Motifs of cadherin and fibronectin type II related sequences and evolution of the receptor-type-protein tyrosine kinases: sequence similarity between proto-oncogene RET and cadherin family. Mol Biol Evol 1993;10:539-51.
22. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317-21.
23. Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M. Characterization of the RET proto-oncogene products expressed in mouse L cells. Oncogene 1993;8:2925-9.
24. Bunone G, Borello MG, Picetti R et al. Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis. Exp Cell Res 1995;217:92-9.
25. Takahashi M, Buma Y, Taniguchi M. Identification of the RET proto-oncogene products in neuroblastoma and leukemia cells. Oncogene 1991;6:297-301.
26. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994;367:380-3.
27. Ikeda I, Ishizaka Y, Tahira T, Suzuki T, Onda M, Sugimura T, Nagao M. Specific expression of the RET proto-oncogene in human neuroblastoma cell lines. Oncogene 1990;5:1291-6.
28. Santoro M, Rosati R, Grieco M et al. The RET proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990;5:1595-8.
29. Tahira T, Ishizaka Y, Itoh F, Nakayasu M, Sugimura T, Nagao M. Expression of the RET proto-oncogene in human neuroblastoma cell lines and its increase during neuronal differentiation induced by retinoic acid. Oncogene 1991;6:2333-8.
30. Miya A, Yamamoto M, Morimoto H et al. Expression of the RET proto-oncogene in human medullary thyroid carcinomas and pheochromocytomas of MEN 2A. Henry Ford Hosp Med J 1992;40:215-9.
31. Borello MG, Pelicci G, Arighi E et al. The oncogenic versions of the Ret and Trk kinases bind Shc and Grb2 adaptor proteins. Oncogene 1994;9:1661-8.
32. Santoro M, Wong WT, Aroca P et al. An epidermal growth factor receptor ret chimera generates mitogenic and transforming signals: Evidence for a ret-specific signalling pathway. Mol Cell Biol 1994;14:663-75.
33. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: Multiple endocrine neoplasia syndrome, type 2. Medicine 1968;47:371-409.
34. Wolfe HJ, Melvin KEW, Cervi-Skinner SJ et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-41.
35. Hennessy JF, Wells SA Jr, Ontjes DA, Cooper CW. A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1974;39:487-95.
36. Lips CJM, Minder WH, Leo JR, Alleman A, Hackeng WHL. Evidence of multicentric origin of the multiple endocrine neoplasia syndrome type 2 A (Sipple's syndrome) in a large family in the Netherlands: Diagnostic and therapeutic implications. Am J Med 1978;64:569-78.
37. Pisano JJ. A simple analysis for normetanephrine and meta-nephrine in urine. Clin Chim Acta 1960;5:406-14.
38. van Gils APG, Falke THM, van Erkel AR et al. MR imaging and MIBG scintigraphy of pheochromocytoma and extra-adrenal functioning paragangliomas. Radiographies 1991;11:37-57.
39. Carney JA, Sizemore GW, Lovestedt SA. Mucosal ganglioneuromatosis, medullary thyroid carcinoma, and pheochromocytoma: Multiple endocrine neoplasia, type 2B. Oral Surg Oral Med Oral Pathol 1976;41:739-52.
40. Farndon JR, Leight GS, Dilley WG et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278-81.
41. Schimke RN, Hartmann WH, Prout TE, Rimoin DL. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas: A possible regulatory defect in the differentiation of chromaffin tissue. 1968;279:1-7.
42. Jackson CE, Norum RA. Genetic mechanisms of neoplasia in MEN 2. Henry Ford Hosp Med J 1989;37:116-9.
43. Melvin KE, Miller HH, Tashjian AH. Early diagnosis of medullary thyroid carcinoma of the thyroid gland by means of the calcitonin assay. N Engl J Med 1971;285:1115-20.
44. Gagel RF, Tashjian AH Jr, Cummings T et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2 A: An 18-year experience. N Engl J Med 1988;318:478-84.
45. DeGroot LJ. Thyroid carcinoma. Med Clin North Am 1975; 59:1233-46.
46. Bergholm U, Adami HO, Bergstrom R, Backdahl M, Akerström G, and the Swedish MTC Study Group. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. Acta Chir Scand 1990;156:37-46.
47. Whitehouse FR, Kernohan JW. Myenteric plexus in congenital megacolon. Study of 11 cases. Arch Intern Med 1948;82:75-111.
48. Badner JA, Seiber WK, Garver KL, Chakravarti A. A genetic-study of Hirschsprung disease. Am J Hum Genet 1990;46:568-80.
49. Anderson DJ. Cell fate determination in the peripheral nervous system: the sympathoadrenal progenitor. J Neurobiol 1993;24:185-98.
50. Mathew CGP, Chin KS, Easton DF et al. A linked genetic marker for multiple endocrine neoplasia syndrome type 2A on chromosome 10. Nature 1987;328:527-8.
51. Simpson NE, Kidd KK, Goodfellow PJ et al. Assignment of multiple endocrine neoplasia syndrome type 2 A to chromosome 10 by linkage. Nature 1987;328:528-30.
52. Norum RA, Lafreiniere RG, O'Neal LW et al. Linkage of the multiple endocrine neoplasia type 2B gene (MEN 2B) to chromosome 10 markers linked to MEN 2A. Genoinics 1990;8:313-7.
53. Lairmore TC, Howe JR, Korte JA et al. Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2 A. Genomics 1991;9:181-92.
54. Howe JR, Lairmore TC, Dou S et al. Presymptomatic identification of carriers of the multiple endocrine neoplasia type 2 A gene using flanking DNA markers. Surgery 1992;112:219-25.
55. Gardner E, Papi L, Easton DF et al. Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. Hum Mol Genet 1993;2:241-6.
56. Mole SE, Mulligan LM, Healey CS, Ponder BAJ, Tunnacliffe A. Localisation of the gene for multiple endocrine neoplasia type 2 A to a 480 kb region in chromosome hand 10q11.2. Hum Mol Genet 1993;2:246-52.
57. Mulligan LM, Kwok JBJ, Healy CS et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia syndrome type 2 A. Nature 1993;363:458-60.
58. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
59. Hofstra RMW, Landsvater RM, Ceccherini I et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia syndrome type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
60. Carlson KN, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994;91:1579-83.
61. Eng C, Smith DP, Mulligan LM et al. Point mutations within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 1994;3:237-41.
62. Eng C, Smith D, Mulligan LM et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-13.
63. Lips CJM, Landsvater RM, Höppener JWM et al. Clinical screening tests as compared with DNA analysis in families with multiple endocrine neoplasia syndrome type 2A. N Engl J Med 1994;331:828-35.
64. Yin L, Ceccherini I, Pasini B et al. Close linkage with the RET proto-oncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung's disease. Hum Mol Genet 1993;2:1803-8.
65. Romeo G, Ronchetto P, Luo Y et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994;367:377-8.
66. Edery P, Lyonnet S, Mulligan LM et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994;367:378-80.
67. Landsvater RM, Rombouts AGM, TeMeerman GJ et al. The clinical implications of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of a MEN 2A kindred. Am J Hum Genet 1993;52:335-42.
68. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;69:820-3.
69. Knudson AG. Hereditary cancer, oncogenes and anti- oncogenes. Cancer Res 1985;45:1437-43.
70. Landsvater RM, Mathew CGP, Smith BA et al. Development of multiple endocrine neoplasia type 2 A does not involve substantial deletions of chromosome 10. Genomics 1989;4:246-50.
71. Nelkin BD, Nakamura Y, White RW et al. Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma. Cancer Res 1989;49:4114-9.
72. Santoro M, Carlomagno F, Romano A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995;267:381-3.
73. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2 A mutations. Mol Cell Biol 1995;15:1613-9.
74. Pasini B, Borello MG, Greco A et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nature Genet 1995;10:35-41.
75. Martucciello G, Bicocchi MP, Dodero P et al. Total colonic aganglionosis associated with interstitial deletion of the long arm of chromosome 10. Pediat Surg Int 1992;7:308-10.
76. Fewtrell MS, Tam PK, Thomson AH et al. Hirschsprung's disease associated with a deletion of chromosome 10 (q11.2 q21.2): a further link with the neurocristopathies? J Med Genet 1994;31:325-7.
77. Santos H, Mateus J, Leal MJ. Hirschsprung's disease associated with polydactyly, unilateral renal agenesis, hypertelorism and congenital deafness. A new autosomal recessive syndrome. J Med Genet 1988;25:204-8.
78. Hofstra RMW, Stelwagen T, Stulp RP et al. RET mutations in MEN 2 associated diseases. Am J Hum Genet 1994; 55: A60.
79. Mulligan LM, Eng C, Attie T et al. Diverse phenotypes associated with exon 10 mutations of the RET proto- oncogene. Hum Mol Genet 1994;3:2163-7.
80. Robinson MF, Furst E, Nunziata V et al. Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2. Henry Ford Hosp Med J 1992;40:249-55.
81. Gagel RF, Levy ML, Donavan DT, Alford BR, Wheeler T, Tschen A. Multiple endocrine neoplasia type 2 A associated with cutaneous lichen amyloidosis. Ann Intern Med 1989;111:802-6.
82. Chabre O, Labal F, Pinel N, Berthod F, Tarel V, Bachelot I. Cutaneous lesion associated with multiple endocrine neoplasia type 2A: lichen amyloidosis or nostalgia paresthetica. Henry Ford Hosp Med J 1992;40:245-8.
83. Pacini F, Fugazzola L, Bevilacqua G, Viacava P, Nardini V, Martino E. Multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis: description of a new family. J Endocrinol Invest 1993;16:295.
84. Ceccherini I, Romei C, Barone F et al. Identification of the Cys634→Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 1994;17:201-4.
85. Schuffenecker I, Billaud M, Calender A et al.. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994; 3: 1939-43.
86. Mulligan LM, Marsh DJ, Robinson BG et al. Genotype-Phenotype correlation in MEN 2: Report of the International RET Mutation Consortium. J Intern Med 1995;238:343-6.
87. Lips CJM, Van der Sluys Veer J, Struyven berg A et al. Bilateral occurrence of pheochromocytoma in patients with the multiple endocrine neoplasia syndrome type 2 A (Sipple's syndrome) Am J Med 1981;70:1051-60.
88. Hofstra RMW. The RET gene and its associated diseases. PhD thesis, University of Groningen, The Netherlands, 1995.